Conjugated capsular saccharides from meningococcal serogroups C, W135 and Yare safe and immunogenic in humans when combined in a single dose. This effectis retained when a conjugated capsular saccharide from serogroup A is added.These conjugated antigens can be stably combined in a single aqueous dosewithout the need for lyophilisation. Broad protection against serogroup Binfection can be achieved by using a small number of defined polypeptideantigens. These polypeptide antigens can be combined with the saccharideantigens without loss of protective efficacy for any of the five serogroups.Efficacy if retained even if a Hib conjugate is added. The efficacy of aserogroup W135 conjugate is enhanced by addition of protein antigens derivedfrom a serogroup B strain. Addition of a Hib conjugate to meningococcalconjugates enhances the overall activity against meningococcus serogroup W135.
